ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0995

Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus

Patricia Katz1, Sofia Pedro2, Jiyoon Choi3 and Kaleb Michaud4, 1UCSF, San Rafael, CA, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3Bristol Myers Squibb, Lawrenceville, NJ, 4University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: glucocorticoids, Health Care, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Glucocorticoids (GCs) have long been a mainstay of treatment for systemic lupus erythematosus (SLE). While GCs do provide benefit, there are potential side effects which increase with dose and duration. GC-associated adverse events have been linked to significant increased health care costs7, although excess healthcare utilization due to GC events has not been examined in SLE. In these analyses, we examine the association of GC use and healthcare utilization.

Methods: Data are from FORWARD, The National Data Bank for Rheumatic Diseases, questionnaires collected from participants with physician-diagnosed SLE and no concomitant RA at 6-month intervals during July 2015 – July 2020. Respondents provided comprehensive health information including GC use and dosage and healthcare use during the prior 6 months. Analyses examined 6-month utilization according to GC use/non-use, as well as by GC dose (0, 1- < 5 mg, 5- < 10 mg, ≥10 mg). For GC users, data were drawn from the questionnaire in which GCs were first reported during the analysis period. Data for non-users were drawn from the first questionnaire completed during the observation period. Adjusted analyses used double selection LASSO1 to form the best fitting model considering the following co-variates: age, sex, race, BMI, comorbidities, education level, smoking, SLE duration, self-reported lupus disease activity, SLE organ damage measured by BILD (Brief Index of Lupus Damage), and other medications. Results of LASSO analyses are reported as incidence rate ratios (IRRs).

1Belloni A, et al. J Economic Perspectives 2014; 28:29.

Results: 512 participants qualified for the analysis; 46.3% reported GC use in at least one 6-month period (Table 1). GC users were less likely to be male or white, had more comorbidities, had lupus of greater duration, were more likely to also be taking immunosuppressive medications, and reported more active SLE and greater disease damage (BILD). In bivariate analyses (Table 2), GC users reported significantly more rheumatology and other doctor visits, and more PT/OT visits. They also reported more lung function, blood, and urine tests. There was no difference between GC users and non-users in the occurrence of a hospitalization, but users had significantly longer hospitalizations. The multivariable LASSO regression analyses (Belloni A, et al. J Economic Perspectives 2014; 28:29) revealed similar results, with significantly IRRs for GC users for rheumatology and other visits, blood and urine tests, and hospitalizations. In analyses based on GC dosage (Table 3), IRRs for rheumatology visits, other medical visits and blood tests were significantly elevated for each dosage group compared to the no-GC group; the highest GC dosage group also had significantly elevated IRRs for lung and urine tests and hospitalizations.

Conclusion: GC use is associated with greater healthcare utilization among this cohort with SLE, even after adjusting for a wide range of sociodemographic and disease-related factors. Additional analyses are needed to explore whether greater GC use reflects more severe disease, and/or whether GC use itself leads to increased healthcare utilization.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: P. Katz, None; S. Pedro, None; J. Choi, Bristol-Myers Squibb(BMS); K. Michaud, None.

To cite this abstract in AMA style:

Katz P, Pedro S, Choi J, Michaud K. Association of Glucocorticoid Use with Healthcare Utilization Among Persons with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-glucocorticoid-use-with-healthcare-utilization-among-persons-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-glucocorticoid-use-with-healthcare-utilization-among-persons-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology